Pulse Biosciences, Inc. (PLSE) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Heavy cash burn ⢠Weak profitability PLSE has strong liquidity with cash far exceeding debt, but its severe losses, negative cash flow, and extreme valuation make the stock fundamentally hard to justify on current results.
Price Behavior
Key Price Behavior Insights: ⢠Sharp rebound ⢠Key support zone ⢠Overhead resistance Support Level: $22.00 to $23.00 Resistance Level: $24.43 PLSE has improved over the last month with a sharp rebound and higher lows, but it remains fragile until it decisively clears $24.43 and holds above $22.00.
Sentiment & News
Key News Insights: ⢠Pivotal enrollment ⢠Leadership expansion ⢠Conference exposure Pulse Biosciences is rapidly advancing its nPulse AFib program with pivotal trial enrollment underway, leadership strengthened, and growing conference visibility supporting continued clinical momentum.
AI Summary
PLSE has moved from a speculative medtech story to a pivotal validation phase, where the investment case now depends on the nPulse cardiac program producing reproducible trial data and eventual reimbursement-backed adoption, but the stock already prices in success while ongoing cash burn and dilution risk mean any clinical or commercialization stumble could hit valuation hard.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |